氰基丙烯酸酯闭合浅表主干静脉术后三年结局:单中心实践队列研究
单中心回顾性队列研究纳入89例患者(110条肢体、156条治疗静脉),评估氰基丙烯酸酯闭合大/小/前/后副隐静脉后中位3.7年的结局。肢体水平原发靶静脉完全闭合率97.3%,修订静脉临床严重程度评分从6降至1,患者满意度97%,但任何治疗静脉通畅与满意度较低相关。
要点
- 氰基丙烯酸酯闭合后中位3.7年原发靶静脉完全闭合率达97.3%。
- 修订静脉临床严重程度评分平均下降4.5分,患者报告结局持续改善。
- 任何治疗静脉通畅者完全满意比例仅41.7%,提示需关注闭合不全。
核心结论
- 氰基丙烯酸酯闭合所有治疗静脉后中位3.7年完全闭合率仍高,临床与患者报告结局持续改善。
- 闭合不全与复发静脉曲张和更差症状、外观及患者满意度相关。
研究设计与样本
- 单中心回顾性队列研究,纳入既往接受氰基丙烯酸酯闭合大隐静脉、小隐静脉、前隐静脉或后副隐静脉的成人患者。
- 共纳入89例患者(76.4%女性;中位年龄53岁),代表110条肢体和156条治疗静脉,采用标准化随访评估。
- 采用广义估计方程分析患者内静脉/肢体的聚类效应。
主要发现
- 肢体水平原发靶静脉完全闭合率为97.3%(107/110;95%CI 91.9%-99.1%)。
- 随访时任何治疗静脉通畅见于10.9%的肢体和7.7%的静脉。
- 修订静脉临床严重程度评分从6(IQR 4-8)降至1(IQR 0-2),平均变化-4.5±2.5(P<.001)。
- Aberdeen静脉曲张问卷评分在配对数据亚组中平均变化-7.7±8.9(P<.001)。
- 新发临床显著静脉曲张见于19.1%的肢体(95%CI 12.7%-27.8%),常涉及前隐静脉。
关键数值与推荐
- 原发靶静脉完全闭合定义为治疗段内无≥5-cm连续性通畅。
- 肢体水平不良事件发生率为20.0%(95%CI 12.9%-29.7%),最常见为局部压痛/静脉炎,未观察到深静脉事件。
- 肢体水平患者满意度为97%(完全/部分满意),但任何治疗静脉通畅时完全满意比例仅41.7%(P<.001)。
- 单变量分析中较高基线体重指数与静脉水平通畅相关(中位33 vs 24 kg/m2;P<.001),探索性多变量模型中仍为独立预测因素。
临床怎么用
- 氰基丙烯酸酯闭合可作为浅表主干静脉功能不全的持久治疗选择,中位3.7年闭合率高且症状改善持续。
- 术后随访应关注任何治疗静脉通畅,因其与静脉曲张复发、症状和外观恶化及满意度下降相关。
- 较高体重指数患者可能需更密切监测静脉通畅情况。
局限性
- 单中心回顾性设计可能限制结果的普遍性。
- 部分患者报告结局分析仅基于配对数据亚组。
- 随访时间中位3.7年,缺乏更长期数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to evaluate mid-term durability, clinical outcomes, and patient-reported outcomes after cyanoacrylate closure (CAC) of superficial truncal veins in routine practice, with limb- and vein-level analyses. METHODS: This was a single-center, retrospective cohort study of adults previously treated with CAC of the great saphenous vein, small saphenous vein, anterior saphenous vein, or posterior accessory saphenous vein, with standardized follow-up assessments. Eligible patients were invited for standardized follow-up including duplex ultrasound, CEAP class, revised Venous Clinical Severity Score, EuroQol 5-dimension survey, and Aberdeen Varicose Vein Questionnaire. The primary endpoint was complete closure of the primary target vein on duplex ultrasound, defined as no ≥5-cm contiguous patency within the treated segment. Secondary endpoints included vein-level patency, new clinically significant varicose veins, adverse events, and satisfaction with symptoms and cosmetic appearance. Analyses accounted for clustering of veins/limbs within patients using generalized estimating equations. RESULTS: The study enrolled 89 patients (76.4% female; median age, 53 years) representing 110 limbs and 156 treated veins. The median time from treatment to follow-up was 3.7 years. Primary target vein complete closure at the limb level was 97.3% (107/110; 95% confidence interval [CI], 91.9%-99.1%). At follow-up, patency in any treated vein was present in 10.9% of limbs and 7.7% of veins. At follow-up, revised Venous Clinical Severity Score decreased from 6 (interquartile range, 4-8) to 1 (interquartile range, 0-2) (mean change, -4.5 ± 2.5; P < .001) and Aberdeen Varicose Vein Questionnaire scores improved among the subset with paired data (mean change, -7.7 ± 8.9; P < .001). New clinically significant varicose veins were present in 19.1% of limbs (95% CI, 12.7%-27.8%), often involving the anterior saphenous vein. Higher baseline body mass index was associated with vein-level patency on univariable analysis (median 33 vs 24 kg/m2; P < .001) and remained an independent predictor in exploratory multivariable models. Patient satisfaction per limb was 97% (completely/somewhat satisfied) but was significantly lower when any treated vein remained patent (completely satisfied 41.7%; P < .001). Limb-level adverse events occurred in 20.0% (95% CI, 12.9%-29.7%), with localized tenderness/phlebitis most commonly encountered; no deep venous events were observed. CONCLUSIONS: Complete closure rates of all treated veins with CAC remain high at a median of 3.7 years post treatment with sustained clinical and patient-reported outcome improvements. Incomplete closure and recurrent varicose veins correlate with worse symptoms, visual appearance and patient satisfaction.
引用
- Gibson K, Glorieux K, Minjarez R, et al. Three-year outcomes after cyanoacrylate closure of superficial truncal veins: A single-center practice cohort study. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 41780674. doi:10.1016/j.jvsv.2026.102470
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。